News
Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...
Fashionista on MSN13h
'GLP-1 Beauty' Is Here — But Is it a Marketing Gimmick?As consumers drop pounds, beauty and wellness brands are dropping products in hopes of cashing in on the rise of weight-loss drugs.
Clinical Trials Arena on MSN16h
FDA clears Caliway’s trial of CBL-514 for localised fat reductionThe top-line outcomes from SUPREME-01 are anticipated between the fourth quarter of 2026 and the first quarter of 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback